scholarly journals Profile of trifluridine/tipiracil hydrochloride in the treatment of metastatic colorectal cancer: efficacy, safety, and place in therapy

2017 ◽  
Vol Volume 10 ◽  
pp. 4599-4605 ◽  
Author(s):  
Yu Sunakawa ◽  
Naoki Izawa ◽  
Takuro Mizukami ◽  
Yoshiki Horie ◽  
Mami Hirakawa ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Tipiracil Hydrochloride

Survival impact on regorafenib (REG) and trifluridine/tipiracil hydrochloride (FTD/TPI) for patients with metastatic colorectal cancer: Single institutional experience.

2020 ◽  
Vol 38 (4_suppl) ◽  
pp. 43-43
Author(s):  
Keigo Chida ◽  
Daisuke Kotani ◽  
Kentaro Sawada ◽  
Yoshiaki Nakamura ◽  
Akihito Kawazoe ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Real World ◽  
Phase Iii ◽  
First Line ◽  
Standard Chemotherapy ◽  
Exon 2 ◽  
The Real ◽  
Real World Setting ◽  
Tipiracil Hydrochloride

43 Background: Regorafenib (REG) and trifluridine/tipiracil hydrochloride (FTD/TPI) demonstrated overall survival (OS) benefit in patients (pts) with metastatic colorectal cancer (mCRC) in the CORRECT and RECOURSE phase III trials. In Japan, REG and FTD/TPI have been approved in 2013 and 2014, respectively. However, little is known about survival impact on these agents in the real-world setting. Therefore, the aim of this retrospective study was to evaluate the effects of REG and FTD/TPI in pts with mCRC. Methods: We collected medical records from consecutive 1142 pts who had been initiated with first-line chemotherapy for mCRC from 2008 to 2016 at National Cancer Center Hospital East. The survival outcomes were compared between pts from 2008 to 2011 (cohort A) and those from 2012 to 2016 (cohort B). This study excluded pts who have not been refractory or intolerant to standard chemotherapy including fluoropyrimidine, oxaliplatin, irinotecan, and anti-EGFR antibody if KRAS exon 2/ RAS wild-type tumors. Results: A total of 590 pts were analyzed (cohort A; N = 236 and cohort B; N = 354). More patients received at least one of REG or FTD/TPI in cohort B (16.1% vs. 59.9%, p < 0.001). The time from initiation to end of standard chemotherapy was comparable between the two cohort (20.0 vs. 17.5 months, p = 0.266). With a median follow-up period of 34.9 months, salvage-line OS (sOS) after standard chemotherapy was significantly longer in cohort B (4.8 vs. 6.6 months, p = 0.001), while there was only a favorable trend in cohort B in terms of OS from start of first-line treatment (27.3 vs. 28.5 months, p = 0.516). In cohort B, pts who sequentially received both of REG and FTD/TPI showed longest sOS (median, both of REG and FTD/TPI; 11.3 months, either REG or FTD/TPI; 7.0 months, neither REG nor FTD/TPI; 3.1 months). Conclusions: Our study showed that REG and FTD/TPI led to prolongation of sOS in the real-world setting, indicating the importance of strategies which make all active agents available to pts with mCRC.

Economic evaluation of trifluridine and tipiracil hydrochloride in the treatment of metastatic colorectal cancer in Greece

2019 ◽  
Vol 8 (3) ◽  
pp. 133-142 ◽  
Author(s):  
George Gourzoulidis ◽  
Nikos Maniadakis ◽  
Dimitrios Petrakis ◽  
John Souglakos ◽  
George Pentheroudakis ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Economic Evaluation ◽  
Metastatic Colorectal Cancer ◽  
Tipiracil Hydrochloride

Self-Reported Adherence to Trifluridine and Tipiracil Hydrochloride for Metastatic Colorectal Cancer: A Retrospective Cohort Study

Oncology ◽  
2016 ◽  
Vol 91 (4) ◽  
pp. 224-230 ◽  
Author(s):  
Kazuo Sugita ◽  
Kazuyoshi Kawakami ◽  
Takashi Yokokawa ◽  
Takahito Sugisaki ◽  
Tomomi Takiguchi ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cohort Study ◽  
Metastatic Colorectal Cancer ◽  
Retrospective Cohort Study ◽  
Retrospective Cohort ◽  
Tipiracil Hydrochloride

scholarly journals Economic Evaluation of Trifluridine and Tipiracil Hydrochloride in The Treatment of Metastatic Colorectal Cancer in Greece

2017 ◽  
Vol 20 (9) ◽  
pp. A434
Author(s):  
G Gourzoulidis ◽  
G Kourlaba ◽  
D Petrakis ◽  
I Souglakos ◽  
G Pentheroudakis ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Economic Evaluation ◽  
Metastatic Colorectal Cancer ◽  
Tipiracil Hydrochloride

scholarly journals Survival Benefit of Crossover Administration of Regorafenib and Trifluridine/Tipiracil Hydrochloride for Patients With Metastatic Colorectal Cancer: Exploratory Analysis of a Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study (REGOTAS)

2021 ◽  
Vol 11 ◽  
Author(s):  
Keigo Chida ◽  
Daisuke Kotani ◽  
Toshikazu Moriwaki ◽  
Shota Fukuoka ◽  
Toshiki Masuishi ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Japanese Society ◽  
Cox Model ◽  
Inclusion Criteria ◽  
Multicenter Observational Study ◽  
Hazard Ratios ◽  
Colon And Rectum ◽  
Using Data ◽  
Tipiracil Hydrochloride

Background: The survival benefits of regorafenib (REG) and trifluridine/tipiracil hydrochloride (TFTD) have been demonstrated in chemorefractory patients with metastatic colorectal cancer (mCRC). However, the effects of crossover administration of REG and TFTD on patient survival remain unclear. The present study evaluated the association between exposure to REG and TFTD and overall survival (OS) in patients with mCRC using data from the REGOTAS study.Patients and Methods: We analyzed patients registered in the REGOTAS study, which retrospectively compared the efficacy and safety of use of REG or TFTD as later-line chemotherapy for chemorefractory mCRC patients. We compared the survival outcomes of cohort A (treated using both REG and TFTD) and cohort B (treated using either REG or TFTD).Results: A total of 550 patients (cohort A, n = 252; cohort B, n = 298) met the inclusion criteria. The median OS was significantly increased in cohort A compared with cohort B [9.6 months (95% confidence interval (CI), 8.9–10.9 months) vs. 5.2 months (95% CI, 4.4–6.0 months), P &lt; 0.001]. Multivariate analysis revealed that cohort A was independently associated with a significant increase in OS [A vs. B: Hazard ratios (HR), 0.58; 95% CI, 0.47–0.72; P &lt; 0.001]. Subgroup analysis adjusted using multivariate Cox model revealed a consistently better trend in most subgroups for cohort A compared with cohort B.Conclusions: Our study revealed prolonged survival in patients treated with REG and TFTD. Therefore, all active agents, including REG and TFTD, should be made available to mCRC patients.

scholarly journals Budget Impact Analysis of Trifluridine and Tipiracil Hydrochloride In The Treatment of Metastatic Colorectal Cancer in Greece

2017 ◽  
Vol 20 (9) ◽  
pp. A423
Author(s):  
G Gourzoulidis ◽  
G Kourlaba ◽  
D Petrakis ◽  
I Souglakos ◽  
G Pentheroudakis ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Impact Analysis ◽  
Budget Impact ◽  
Budget Impact Analysis ◽  
Tipiracil Hydrochloride
Sign in / Sign up

Export Citation Format

Share Document